Patents by Inventor Dimitrios Iliopoulos

Dimitrios Iliopoulos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250042850
    Abstract: Disclosed herein are compounds (e.g., pyrrole compounds, carboxy pyrroles, etc.), including pharmaceutical compositions that include one or more of such compounds (e.g., carboxy pyrroles). Also disclosed are methods of making carboxy pyrrole compounds. Also disclosed herein are methods of treating diseases and/or conditions (e.g., inflammation and/or cancer) with the carboxy pyrrole compounds disclosed herein.
    Type: Application
    Filed: January 24, 2022
    Publication date: February 6, 2025
    Inventors: Dimitrios Iliopoulos, David G. Ho, Iordanis Karagiannidis, Phithi Nguyen, Dimitra Chalkia
  • Publication number: 20240199597
    Abstract: Disclosed herein are quinazolinyl compounds, compositions, and methods of use thereof. The compounds may be used in the treatment of kinase-related disorders (including cancer, autoimmune disease, and Duchenne muscular dystrophy).
    Type: Application
    Filed: March 22, 2022
    Publication date: June 20, 2024
    Inventors: Dimitrios Iliopoulos, David G. Ho, Iordanis Karagiannidis, Phithi Nguyen, Dimitra Chalkia
  • Patent number: 11952362
    Abstract: The present disclosure provides compounds and compositions capable of treating cancer or an autoimmune disease, such as Crohn's disease, and methods of use thereof.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: April 9, 2024
    Assignee: The Regents of the University of California
    Inventors: Dimitrios Iliopoulos, Michael E. Jung, Jonghoon Kim, Jill M. Hoffman, Iordanes Karagiannides
  • Publication number: 20230159498
    Abstract: Disclosed herein are quinazolinyl compounds, compositions, and methods of use thereof. The compounds may be used in the treatment of autoimmune disorders or cancer.
    Type: Application
    Filed: October 6, 2022
    Publication date: May 25, 2023
    Inventors: Dimitrios Iliopoulos, David G. Ho, Iordanis Karagiannidis, Phithi Nguyen, Dimitra Chalkia
  • Patent number: 11485728
    Abstract: Disclosed herein are quinazolinyl compounds, compositions, and methods of use thereof. The compounds may be used in the treatment of autoimmune disorders or cancer.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: November 1, 2022
    Assignee: Athos Therapeutics, Inc.
    Inventors: Dimitrios Iliopoulos, David G. Ho, Iordanis Karagiannidis, Phithi Nguyen, Dimitra Chalkia
  • Publication number: 20220073498
    Abstract: Disclosed herein are quinazolinyl compounds, compositions, and methods of use thereof. The compounds may be used in the treatment of autoimmune disorders or cancer.
    Type: Application
    Filed: November 19, 2021
    Publication date: March 10, 2022
    Inventors: Dimitrios Iliopoulos, David G. Ho, Iordanis Karagiannidis, Phithi Nguyen, Dimitra Chalkia
  • Publication number: 20210309634
    Abstract: The present disclosure provides compounds and compositions capable of treating cancer or an autoimmune disease, such as Crohn's disease, and methods of use thereof.
    Type: Application
    Filed: July 22, 2019
    Publication date: October 7, 2021
    Inventors: Dimitrios Iliopoulos, Michael E. Jung, Jonghoon Kim, Jill M. Hoffman, Iordanes Karagiannides
  • Patent number: 10865252
    Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: December 15, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
  • Publication number: 20200031950
    Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.
    Type: Application
    Filed: March 6, 2018
    Publication date: January 30, 2020
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
  • Patent number: 10233463
    Abstract: This application discloses methods of treating, preventing, and diagnosing colorectal cancer and IBD in a subject comprising administering an effective dose of antisense miR-133? or AFTPH to the subject or detecting expression levels of miR-133? and AFTPH.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: March 19, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Charalabos Pothoulakis, Dimitrios Iliopoulos, Ka Man Law
  • Publication number: 20180273638
    Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.
    Type: Application
    Filed: March 6, 2018
    Publication date: September 27, 2018
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
  • Patent number: 9938354
    Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogenesis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: April 10, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
  • Publication number: 20140328858
    Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.
    Type: Application
    Filed: May 2, 2014
    Publication date: November 6, 2014
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
  • Patent number: 8617818
    Abstract: MicroRNA (miRNA) profiling of cells showed unique miRNA signatures for each of three Akt isoforms. Among differentially regulated miRNA species, the miR-200 family was downregulated in Akt2-expressing cells. Akt1 knockdown inhibited expression of miR-200 and promoted TGF?-induced epithelial-mesenchymal-transition (EMT) and a stem cell like phenotype. Carcinomas developing in MMTV-cErb2/Akt1?/? mice exhibited increased invasiveness because of EMT induced by miR-200 downregulation. EMT was found to be controlled by miRNA species that are regulated by the balance between Akt1 and Akt2, rather than overall Akt levels.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: December 31, 2013
    Assignees: Tufts Medical Center, President and Fellows of Harvard College
    Inventors: Philip N. Tsichlis, Christos Polytarchou, Dimitrios Iliopoulos
  • Publication number: 20120220664
    Abstract: Disclosed herein is a method for treating a tumor in a subject in need thereof comprising administering an enhancing amount of metformin and a reduced amount of one or more chemotherapeutic agents. One example of an enhancing amount of metformin is about 250 mg/day. Also disclosed is a Untreated method for preventing cancer or delaying the recurrence of cancer in a subject comprising administering an effective amount of metformin to the subject. In one example of such a method, the amount of metformin is about 75 mg/day. Also disclosed is a composition comprising an enhancing amount of metformin, and a reduced amount of one or more chemotherapeutic agents and a pharmaceutically acceptable carrier. Kits comprising metformin and one or more chemotherapeutic agents are also disclosed.
    Type: Application
    Filed: August 25, 2010
    Publication date: August 30, 2012
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Kevin Struhl, Heather Hirsch, Dimitrios Iliopoulos
  • Publication number: 20120021983
    Abstract: MicroRNA (miRNA) profiling of cells showed unique miRNA signatures for each of three Akt isoforms. Among differentially regulated miRNA species, the miR-200 family was downregulated in Akt2-expressing cells. Akt1 knockdown inhibited expression of miR-200 and promoted TGF?-induced epithelial-mesenchymal-transition (EMT) and a stem cell like phenotype. Carcinomas developing in MMTV-cErb2/Akt1?/? mice exhibited increased invasiveness because of EMT induced by miR-200 downregulation. EMT was found to be controlled by miRNA species that are regulated by the balance between Akt1 and Akt2, rather than overall Akt levels.
    Type: Application
    Filed: September 30, 2011
    Publication date: January 26, 2012
    Applicants: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, TUFTS MEDICAL CENTER, INC.
    Inventors: Philip N. Tsichlis, Christos Polytarchou, Dimitrios Iliopoulos